These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553 [TBL] [Abstract][Full Text] [Related]
30. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version]. Malzkorn B; Reifenberger G Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013 [TBL] [Abstract][Full Text] [Related]
31. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746 [TBL] [Abstract][Full Text] [Related]
32. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
33. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
34. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687 [TBL] [Abstract][Full Text] [Related]
35. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562 [TBL] [Abstract][Full Text] [Related]
36. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
37. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance. Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574 [TBL] [Abstract][Full Text] [Related]
38. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545 [TBL] [Abstract][Full Text] [Related]